Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure
Key facts
- Who runs it
- Tianjin Medical University Cancer Institute and Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 35 people, planned
- Starts
- 8 Dec 2026
- Expected to end
- 8 Dec 2030
- Type of study
- Interventional
- Treatments tested
- Pirtobrutinib
- Sonrotoclax
- Rituximab injection
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (33)Hide the full registry criteria
Who can take part
- 1.Histopathologically-confirmed mantle cell lymphoma (MCL) with documented t(11;14)(q13;q32) translocation and/or cyclin-D1 over-expression, accompanied by relevant biomarkers (e.g., CD5, CD19, CD20, or PAX5). All subjects must provide sufficient archived or fresh tumor tissue samples for immunohistochemistry (IHC) testing
- 2.Age ≥ 18 years, male or female
- 3. Received at least one prior line of systemic therapy containing a covalent BTK-inhibitor
- 4.Histopathologically-confirmed high-risk MCL, defined as meeting at least one of the following criteria: POD24, complex karyotype, TP53 mutation, del(17p), high-risk MIPI score, blastoid / pleomorphic variant, Ki-67 ≥ 30 %, bulky disease
- 5.Presence of at least one measurable lesion. Measurable disease is defined as a tumor mass ≥ 1.5 cm in one or two dimensions; splenic lesions are considered measurable
- 6.Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- 7.Adequate hematological function:; Absolute neutrophil count (ANC) ≥ 1 × 10⁹/L without growth-factor support within 7 days prior to testing; Platelet count ≥ 75 × 10⁹/L, or ≥ 50 × 10⁹/L in the setting of bone-marrow involvement; no growth-factor support or transfusion within 7 days prior to testing
- 8.Adequate hepatic function:; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); Total bilirubin ≤ 2 × ULN, except for subjects with confirmed Gilbert syndrome, in whom bilirubin up to 5 × ULN is permitted
- 9.Adequate renal function:; Creatinine clearance ≥ 60 mL/min (estimated by the Cockcroft-Gault formula, or eGFR calculated using the Modification of Diet in Renal Disease [MDRD] formula); Serum creatinine ≤ 1.5 × ULN
- 10.International normalized ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN
- 11.For females of child-bearing potential, two negative pregnancy tests (at least one serum pregnancy test) are required prior to treatment initiation. The first test must be performed 10-14 days before the first dose of sonrotoclax; the second test must be performed within 24 hours before the first dose of sonrotoclax
- 12.Females of child-bearing potential must agree to use two reliable contraceptive methods (one highly-effective method plus one additional effective method), starting 4 weeks prior to initiating sonrotoclax, throughout study participation, and for at least 90 days after the last dose of pirtobrutinib or 12 months after the last dose of rituximab (whichever is longer). Highly-effective contraception includes abstinence, hysterectomy, bilateral oophorectomy with 6-month amenorrhea, intrauterine system, and hormonal contraception (e.g., injectable or oral contraceptives). Male subjects must be vasectomized or use barrier contraception while their female partners employ effective contraception as described above. Male subjects must refrain from sperm donation during the study and for at least 90 days after the last dose of pirtobrutinib and sonrotoclax, or for 12 months after the last dose of rituximab (whichever is longer)
- 13.Estimated life expectancy > 3 months
- 14.Capable of providing written informed consent, and able to understand and comply with study requirements
Who cannot take part
- 1. Current or suspected central nervous system (CNS) involvement of mantle cell lymphoma, or a prior history of CNS-involved disease
- 2. Prior treatment with a BCL-2 inhibitor or pirtobrutinib
- 3. Major surgery within 4 weeks prior to screening. Note: If a subject has undergone major surgery, they must have fully recovered from any toxicities and/or complications of the intervention before receiving the first dose of study drug
- 4. History of other active malignant disease within 2 years before entering the study, with the following exceptions: (1) adequately-treated carcinoma in-situ of the cervix; (2) localized basal-cell or squamous-cell skin carcinoma; (3) previously-diagnosed malignancy that has been controlled with curative-intent local treatment (surgery or other modalities)
- 6. Known human immunodeficiency virus (HIV) infection, or serology suggestive of active hepatitis B or hepatitis C infection, as follows:; Subjects who are hepatitis B core antibody (HBcAb)-positive and hepatitis B surface antigen (HBsAg)-negative must have a negative HBV-PCR result prior to the first study-drug dose. Subjects who are HBsAg-positive or HBV-DNA-positive are excluded; Subjects with positive hepatitis C antibody must have a negative HCV-RNA result before the first dose of study drug. Subjects with positive HCV-PCR are excluded
- 7. Clinically significant cardiovascular disease, including:; Myocardial infarction within 6 months before screening; Unstable angina within 3 months before screening; Clinically significant arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes); QTcF (Fridericia correction) > 480 msec; History of second-degree type-II or third-degree atrioventricular (AV) block; New York Heart Association (NYHA) class III or IV congestive heart failure
- 9. History of deep-vein thrombosis (DVT) or pulmonary embolism (PE) within the previous 12 months
- 10. History of a major cerebrovascular event (including stroke or intracranial hemorrhage) within 6 months before the first dose of study drug
- 11. Requiring ongoing treatment with strong or moderate CYP3A inhibitors or CYP3A inducers. Subjects who have received strong/moderate CYP3A inhibitors or inducers within 7 days (or less than 5 drug half-lives) before the first study-drug dose are excluded. Subjects receiving moderate CYP3A inhibitors may be considered for enrollment after a minimum 7-day wash-out period
- 12. Requiring anticoagulation with warfarin or an equivalent vitamin-K antagonist (e.g., phenprocoumon) within 7 days of the first study-drug dose
- 5. Active, uncontrolled systemic fungal, bacterial, or viral infection (defined as persistent signs/symptoms related to infection with no improvement despite appropriate antibiotic, antiviral, and/or other therapy)
- 8. History of severe bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring transfusion or other medical intervention
- 13. Active bleeding gastrointestinal ulcer, except cases attributable to mantle-cell lymphoma identified on endoscopy
- 14. Known hypersensitivity to urate-lowering agents
- 15. History of toxic epidermal necrolysis or Stevens-Johnson syndrome
- 17. Known hypersensitivity to any of the study drugs
- 18. Any psychiatric or cognitive disorder that may limit the subject's ability to understand, provide informed consent, or comply with study requirements
- 19. Subjects with active drug or alcohol abuse. Any life-threatening disease, medical condition, or organ-system dysfunction that, in the investigator's judgment, may jeopardize subject safety or introduce additional risks to participation in the study
- 16. Pregnant or breastfeeding women
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Mantle cell lymphoma
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This single-arm, multicenter, open-label phase II study aims to evaluate the efficacy and safety of pirtobrutinib plus sonrotoclax and rituximab in adults with high-risk relapsed/refractory mantle cell lymphoma after failure of prior covalent BTK-inhibitor therapy. **Approximately 35 patients are planned to be enrolled**. Subjects will receive 28-day cycles of the triple-drug regimen. Participants achieving complete response with undetectable MRD at cycle 12 may stop treatment; others may continue up to 24 cycles. The primary endpoint is the CR-uMRD rate at cycle 12. Secondary endpoints include ORR, CRR, DOR, PFS, OS and safety. Exploratory biomarker and quality-of-life analyses will also be performed.
The group in the trial
- Pirtobrutinib + Sonrotoclax + Rituximab Combination TherapyTreatment being tested
Patients receive pirtobrutinib 200 mg once daily continuously, sonrotoclax dose-escalated to 320 mg once daily, plus rituximab 375 mg/m² on Day 1 of each 28-day cycle. Treatment may stop at Cycle 12 for patients achieving CR-uMRD, with a maximum treatment duration of 24 cycles.
Treatment: Pirtobrutinib, Sonrotoclax, and Rituximab injection
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multi-center, Single-arm, Open-label Phase II Clinical Study of Pirtobrutinib Combined With Sonrotoclax and Rituximab in Patients With Relapsed/Refractory High-risk Mantle Cell Lymphoma Previously Treated With a Covalent BTKi.
- Criteria questions
- Built from NCT07944651, who can take part
- Record updated
- 18 November 2026